Your World of Legal Intelligence
 India | 1-800-335-6202

U.S. Patent and Trademark Office Releases Apellis Pharmaceuticals's Patent Application for Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Related Compositions and Methods

Document Cited in Related
Vincent
Published date27 March 2023
Publication titleGlobal IP News (India)
The patent application number is US202217673703 20220216. The patent publication number is US2023091471 (A1). International Patent Classification codes are A61K38/00, A61K38/10, A61K47/54, A61K47/55, A61K47/60, C07K14/47 and C07K7/08. Cooperative Patent Classification codes are A61K38/005 (EP, US), A61K38/10 (EP, US), A61K47/542 (US), A61K47/55 (US), A61K47/60 (EP, US), A61P37/00 (EP), A61P37/06 (EP), A61P43/00 (EP), C07K14/472 (EP, US), C07K7/08 (EP, US), A61K38/00 (EP and US)

According to the abstract released by the U.S. Patent and Trademark Office: "In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT